Summit Therapeutics Inc.
Financials
Valuation Metrics
Summit Therapeutics Inc.'s Market Cap is $11.81B. At end of 2025 it was $13.08B. Ranked #783 of 3,118 in US market (top 25%), #246 of 1,474 on NASDAQ (top 17%), #37 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 14%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $11.81B | US#783/3,118 Sec#37/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-856M | US—/3,118 Sec—/265 |
| Total Assets | $752M | US#2,591/3,118 Sec#124/265 |
| Net Assets | $630M | US#2,069/3,118 Sec#92/265 |
| Employees | 265 | US#2,431/3,118 Sec#116/265 |
| Value | ||
| P/B | 18.75x | US#2,786/3,118 Sec#217/265 |
| FCF Yield | -3.44% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -135.89% | US#2,814/3,118 Sec#213/265 |
| Financial Health | ||
| Debt Ratio | 19.40% | US#217/3,118 Sec#75/265 |
| Total Debt | $20M | US#2,740/3,118 Sec#187/265 |
| FCF | $-407M | US#2,874/3,118 Sec#245/265 |
| Cash | $419M | US#1,180/3,118 Sec#67/265 |
| Current Ratio | 6.96x | US#352/3,118 Sec#110/265 |
| Performance | ||
| 1Y Return | -21.71% | US#2,252/3,118 Sec#178/265 |
| 1M Return | -11.66% | US#2,199/3,118 Sec#153/265 |
| From 52W High | -49.35% | US#2,505/3,118 Sec#186/265 |
| 1Y MDD | -52.88% | US#2,501/3,118 Sec#176/265 |
| Trading | ||
| Volume | 3,421,302 shares | US#650/3,118 Sec#50/265 |
| Trading Value | $52M | US#1,304/3,118 Sec#80/265 |
| Per Share | ||
| EPS | $-1.07 | US—/3,118 Sec—/265 |
| BPS | $0.79 | US#2,717/3,118 Sec#207/265 |
Company Info
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.